JPMorgan has given Cipla an ‘overweight’ rating with a target of Rs 1,210 per share. The company has not commented on the nature of 8 observations received from USFDA for Pithampur plant. The said plant is one of Cipla’s key manufacturing facilities, along with the Goa and Invagen plant in the US. Advair, one of […]